ECT is comprised of two primary services, Protocol+ for the registration of trials and Results Services for the publications of trial results.
EveryClinicalTrial (ECT), a service to address the registration and trial results requirements of ClinicalTrials.gov, is now available. ECT is comprised of two primary services, Protocol+ for the registration of trials and Results Services for the publications of trial results, and takes advantage of the company’s translational tools that offer efficiencies for uploading protocols to the site. The company predicts the service will be beneficial for all sponsors and institutions, but for those who only have a few trials a year, it offers a low-cost solution for a convoluted process. ECT Founder Colin Miller is formerly with BioClinica.
Read the full release.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.